Dr. Aaditya Udupa, MD (Audi), has over 12 years of experience in life sciences and consulting. His primary area of expertise is transaction advisory, and he has collaborated with both pharmaceutical companies and private equity clients to evaluate a range of innovative assets, product portfolios, CDMOs, and pharma companies. He has advised clients on transactions involving Argenx, Viatris, Norgine, Neopharmed, Takeda, and others.

Dr. Udupa works with pharmaceutical companies on corporate strategy and transaction advisory, providing guidance on go-to-market strategies, commercial setup, product forecasting, clinical trial strategy, and both buy-side and sell-side support. He specializes in oncology and neurology, having collaborated with a range of large and mid-sized pharmaceutical companies in these therapeutic areas. Additionally, he has extensive experience with US and European biosimilars and rare disease products, helping clients navigate complex regulatory landscapes and optimize market entry strategies. His expertise also extends to digital health, where he has worked on integrating innovative technologies into traditional pharma models to enhance patient outcomes.

Dr. Udupa is a medical doctor by training and has completed an MBA post his medical education. In previous roles, he worked with a venture capital firm specializing in the US oncology space and with IQVIA in the financial institutions consulting team. He has also served as a Director in the commercial strategy team at Clarivate.